Our lab is focused on several aspects of translational molecular oncology, including the development of biomarkers for head and neck cancers, high throughput screens to identify novel anti-cancer therapeutics and stem cell regenerative therapy. Using DNA, RNA and protein extracted from diagnostic human cancer samples, we are in the process of conducting multi-omic global expression analyses. Preliminary data are very promising, and in addition to identifying multi-dimensional predictive/prognostic signatures for improving cancer patient management, we are also studying their related pathways and biological functions in preclinical models of human cancers. Automated robotic screens are being used to identify corresponding novel anti-cancer compounds, and characterization of these potential new therapeutics is underway. Finally, we are also interested in understanding how adipose derived stem cells may aid in tissue regeneration after treatment with ionizing radiation.
Dysregulation of the MiR-449b target TGFBI alters the TGFβ pathway to induce cisplatin resistance in nasopharyngeal carcinoma.
Oncogenesis. 2018 May 22;7(5):40
Proteomic Analysis of Cancer-Associated Fibroblasts Reveals a Paracrine Role for MFAP5 in Human Oral Tongue Squamous Cell Carcinoma.
J Proteome Res. 2018 May 02;:
Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint.
Cancer Res. 2018 Apr 23;:
Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Feb 01;:
Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.
Int J Radiat Oncol Biol Phys. 2018 Jan 09;:
Curr Oncol. 2017 Dec;24(6):e518-e523
J Healthc Manag. 2017 Sep/Oct;62(5):302-313
Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study.
Br J Cancer. 2017 Aug 22;:
Lancet Oncol. 2017 May;18(5):e238
Source Code Biol Med. 2017;12:1
Senior Scientist, Princess Margaret Cancer Centre
Professor, Radiation Oncology, University of Toronto
Professor, Medical Biophysics, University of Toronto
Professor, Otolaryngology, University of Toronto
Chief, Radiation Medicine Program, Princess Margaret Cancer Centre
Chair, Radiation Oncology, University of Toronto